COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Phase I/II Trial of Endometrial Regenerative Cells (ERC) in Patients With Critical Limb Ischemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01558908
Recruitment Status : Unknown
Verified March 2012 by Medistem Inc..
Recruitment status was:  Not yet recruiting
First Posted : March 20, 2012
Last Update Posted : March 20, 2012
Information provided by (Responsible Party):
Medistem Inc.

Brief Summary:
This is a 15 patient clinical trial assessing the safety and feasibility of using Endometrial Regenerative Cells (ERC) in patients with critical limb ischemia (CLI) that are not eligible for surgical or catheter-based interventions. Three doses of ERC will be examined. The hypothesis is that ERC administration will be well-tolerated and possibly induce a therapeutic benefit.

Condition or disease Intervention/treatment Phase
Peripheral Vascular Diseases Biological: Administration of ERC Phase 1 Phase 2

Detailed Description:

The purpose of the trial is to determine safety of intramuscularly derived menstrual mesenchymal stem cells (otherwise known as Endometrial Regenerative Cells, or ERC) in patients with critical limb ischemia ineligible for revascularization. Safety will be defined as freedom from treatment associated adverse events. Efficacy parameters will comprise endpoints of changes in ankle-brachial index, toe-brachial index, TcPO2, ulcer healing, rest pain, quality of life, and reduction in amputation.

Patients will receive 25, 50, or 100 million menstrual derived mesenchymal stem cells (Endometrial Regenerative Cells: ERC) in ten injections of 2.5, 5, or 10 million mesenchymal stem cells suspended in a volume of 1 ml per injection. Injections will be spaced at least 2 centimeters apart from each other in the gastrocnemius muscle above the failed vascular perfusion area.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Allogeneic,Unrelated, Menstrual Derived, Mesenchymal Stem Cell-Like, Endometrial Cells; Administered Intramuscular
Study Start Date : May 2012
Estimated Primary Completion Date : May 2013
Estimated Study Completion Date : July 2013

Arm Intervention/treatment
Experimental: Intramuscular injection of ERC Biological: Administration of ERC
Patients will be treated with either 25 million, 50 million, or 100 million ERC by intramuscular injection.

Primary Outcome Measures :
  1. Safety [ Time Frame: 52 weeks ]
    Adverse and serious events recorded

Secondary Outcome Measures :
  1. Efficacy [ Time Frame: 12 weeks ]
    Improvements post-treatment in rest pain (VAS), toe pressure and ABI, transcutaneous oximetry and ulcer status (with picture).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Non-pregnant patients with critical limb ischemia, Rutherford IV-V, manifested as rest pain or tissue loss, or with disabling claudication, manifested as exercise induced thigh or calf pain that impairs activities of daily living, who are not candidates for surgical bypass or angioplasty due to unfavorable arterial anatomy or absence of adequate autogenous vein for a below-knee bypass.
  2. Patients over 18 years of age with an expected survival of more than one year after treatment.
  3. Unreconstructable arterial disease will be determined by a vascular surgeon who is not participating in the study. Unreconstructable arterial disease is defined by atherocclusive lesions within the arterial tree of the extremity that due to extent or morphology are not amenable to surgical bypass or PTCA and stenting.
  4. Patients with a maximum of 3 non-healing 'flat' surface or 'transdermal' ulcers Grades 1-2, no ulcer bigger than 2 centimeters (2)
  5. Patients with unfavorable anatomy or who are medically unfit to undergo bypass as determined by a vascular surgeon who is not participating in the study.
  6. Vascular imaging (eg angiogram or MRA) to determine vascular anatomy must be conducted within 3 months of study entry.
  7. Patients with low/absent perfusion in the area at or below the gastrocnemius muscle
  8. Objective evidence of severe peripheral arterial disease will include an ankle brachial index (ABI) of less than 0.55, and/or a resting toe brachial index (TBI) of less than 40.
  9. Patients must be competent to give consent.
  10. No history of malignant disease except for nonmelanoma skin cancer, no suspicious findings on chest x-ray, mammography (women over age 35) , Papanicolaou smear (women over age 40), a normal fecal occult blood (over age 50) and a normal prostate specific antigen (men over age 45).
  11. Patients must have a prothrombin Time (PT) between 12-14 seconds, a partial thromboplastin time (PTT) of 18-28 seconds, and platelet count >100,000/microliter
  12. Patients must have white blood cell count (4.1-10.9x10(3) cells/µL)
  13. Normal liver function tests (AST 8 - 20 U/L, ALT 8 - 20 U/L, and total bilirubin 0.1 - 1.0 mg/dL)
  14. Patients must be male or post menopausal women.

Exclusion Criteria:

  1. Patients with evidence of active proliferative retinopathy.
  2. Patients with poorly controlled diabetes mellitus (HbA1C > 8.5%).
  3. Patients with renal insufficiency (Creatinine > 2.5) or failure.
  4. Infection as evidenced by WBC count of >15,000 k/cumm and/or temperature >38C.
  5. Cellulitis in the afflicted limb that in the opinion of the investigators would require the use of antibiotics or evidence of osteomyelitis corroborated by radiographic or scintigraphic examination.
  6. Pregnant women (women capable of childbearing must have a negative pregnancy test)
  7. Cognitively impaired adult
  8. Lower extremity venous disease with pitting edema.
  9. History of organ transplant.
  10. Patients with ulcer exudates, dry gangrene or exposed bone.
  11. Allergies to beta-lactam antibiotics, amphotericin B, or streptomycin
  12. Cardiovascular conditions:

    • Exercise limiting angina (Canadian Cardiovascular Society Class > 3
    • Congestive heart failure (New York Heart Association class > 3
    • Unstable angina
    • Acute ST elevation myocardial infarction (MI) within 1month
    • Transient ischemic attack or stroke within 1 month
    • Severe valvular disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01558908

Layout table for location contacts
Contact: Michael P Murphy, MD 317-630-8288
Contact: Janet Klein, RN (317) 962-0287

Layout table for location information
United States, Indiana
Indiana University School of Medicine
Indianapolis, Indiana, United States
Contact: Michael P Murphy, MD    317-630-8288   
Principal Investigator: Michael P Murphy, MD         
Sponsors and Collaborators
Medistem Inc.
Layout table for investigator information
Principal Investigator: Michael P Murphy, MD Indiana University

Additional Information:
Layout table for additonal information
Responsible Party: Medistem Inc. Identifier: NCT01558908    
Other Study ID Numbers: MEDS-027
First Posted: March 20, 2012    Key Record Dates
Last Update Posted: March 20, 2012
Last Verified: March 2012
Keywords provided by Medistem Inc.:
critical limb ischemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Peripheral Vascular Diseases
Peripheral Arterial Disease
Cardiovascular Diseases
Arterial Occlusive Diseases